| Document |
Document Title |
|
WO/2022/150461A1 |
The present disclosure relates to methods of treating a ciliopathy, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound or pharmaceutical composition thereof, wherein the comp...
|
|
WO/2022/148403A1 |
Provided in the present invention is the use of an inhibitor targeting IL-17C in the treatment of inflammation-associated chronic kidney diseases. It is found for the first time in the present invention that interleukin17C (IL-17C) is a ...
|
|
WO/2022/143893A1 |
The present application relates to a bladder perfusion pharmaceutical composition, comprising an immunological adjuvant or a soluble salt thereof, and a chemical drug capable of causing immunogenic cell death. When the immunological adju...
|
|
WO/2022/143845A1 |
Disclosed are a nitrogen-containing bridged heterocyclic compound, a preparation method therefor, and a medical application thereof. Specifically, disclosed are a nitrogen-containing bridged heterocyclic compound represented by general f...
|
|
WO/2022/143897A1 |
The present invention provides a polymorphic substance of a A-decarburization-5α androstane compound (ACP-2), an application thereof and a preparation method therefor. Specifically, the present invention relates to a polymorphic substan...
|
|
WO/2022/146061A1 |
Provided is a pharmaceutical composition comprising as active ingredients: 5mg of tadalafil or a pharmaceutically acceptable salt thereof; and 0.5 mg of dutasteride or a pharmaceutically acceptable salt thereof, wherein the dissolution r...
|
|
WO/2022/145656A1 |
The present invention relates to a composition for preventing, ameliorating, or treating eye diseases, the composition containing Micrococcus luteus-derived vesicles as an active ingredient. The present inventors have confirmed that when...
|
|
WO/2022/145680A1 |
The present invention relates to extracellular vesicles derived from Micrococcus luteus and use thereof and, in particular, to a composition and the like for ameliorating, preventing or treating neutrophilic pulmonary disease, comprising...
|
|
WO/2022/145443A1 |
The purpose of the present invention is to establish a means for treating chronic kidney diseases including Alport's syndrome. The present invention provides a pharmaceutical composition characterized by containing: a) a renin/angiotensi...
|
|
WO/2022/143940A1 |
A series of piperidine-substituted benzoic acid compounds and the use thereof, and specifically disclosed is a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/145710A1 |
The present invention relates to extracellular vesicles derived from Micrococcus luteus, and a use thereof and, more specifically, to a composition and the like for alleviating, preventing, or treating neurodevelopmental, neurological or...
|
|
WO/2022/146614A1 |
Among the various aspects of the present disclosure is the provision of a method of treating or preventing kidney disease in a subject in need thereof. Another aspect of the present disclosure provides for a method of reducing a number o...
|
|
WO/2022/145711A1 |
The present invention relates to Micrococcus luteus-derived extracellular vesicles and use thereof and, more specifically, a composition comprising Micrococcus luteus-derived extracellular vesicles as an active ingredient for alleviation...
|
|
WO/2022/135322A1 |
A nanocomposite containing a hydrophobic substance and a preparation method therefor, wherein the nanocomposite comprises an emulsion layer, which is obtained by means of emulsifying a hydrophobic substance, such as botulinum toxin, and ...
|
|
WO/2022/138257A1 |
The present invention provides a new substance having a PDE5 inhibitory effect. This PDE5 inhibitor includes a pupae powder or an extract thereof.
|
|
WO/2022/138792A1 |
The purpose of the present invention is to provide a suitable form for a compound, and an active pharmaceutical ingredient thereof, for the prevention and/or treatment of a disease associated with the activation of an EP2 receptor, said ...
|
|
WO/2022/133551A1 |
The present application is directed towards compounds, pharmaceutically acceptable salts or prodrugs thereof, which are inhibitors of Histone Deacetylase (HDAC) binding or function. The compounds especially may have some selectivity for ...
|
|
WO/2022/138791A1 |
The purpose of the present invention is to provide a medicine for the prevention and/or treatment of a disease caused by activation of an EP2 receptor, said medicine containing, as an active ingredient, a compound having an antagonistic ...
|
|
WO/2022/140654A1 |
The present disclosure relates to compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds and salts thereof.
|
|
WO/2022/140180A1 |
Provided herein are methods for treating kidney disease comprising administering a therapeutic peptide alone or together with one or more agents. Provided herein are methods for reducing kidney damage.
|
|
WO/2022/138258A1 |
The present invention provides a new substance having a PDE5 inhibitory effect. This PDE5 inhibitor includes Paecilomyces tenuipes powder or an extract thereof.
|
|
WO/2022/135523A1 |
Disclosed in the present invention is an application of a BMP4 protein in preparation of a drug for treating or preventing a fibroproliferative disease of an object, wherein the BMP4 protein is a free BMP4 protein or a recombinant vector...
|
|
WO/2022/135534A1 |
A novel substituted nitrogen-containing bicyclic compound and a pharmaceutical composition containing the compound, capable of being used as chymase inhibitors. Also provided are methods for preparing the compound and pharmaceutical comp...
|
|
WO/2022/136486A1 |
The present application discloses compounds of e.g. formulae (2), (1A), (1B) or (1C) as selective atypical chemokine receptor 3 (ACKR3) modulators for the treatment of e.g. cancer, atherosclerotic vascular disease, cardiovascular disease...
|
|
WO/2022/137178A1 |
The present disclosure is directed to a method of treating overactive bladder comprising orally administering to a patient in need thereof a therapeutically effective amount of vibegron, wherein the patient is concomitantly receiving dig...
|
|
WO/2022/140677A1 |
The present disclosure relates to compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds and salts.
|
|
WO/2022/132066A1 |
The present invention relates to a homogenous pharmaceutical composition comprising propiverine or a pharmaceutically acceptable salt thereof wherein the composition is in an oral solid dosage form with improved pharmaceutical properties.
|
|
WO/2022/129618A1 |
A method for preparing at least one watercress extract, which method comprises: (a) macerating watercress to form an aqueous watercress intermediate; (b) heating at least part of the aqueous watercress intermediate to coagulate at least ...
|
|
WO/2022/127654A1 |
An anti-fibrosis pharmaceutical composition and an application thereof. The anti-fibrosis pharmaceutical composition specifically comprises: (a) an NRP1 inhibitor and/or a HIF2α inhibitor; and (b) an EPCR pathway activator that promotes...
|
|
WO/2022/127917A1 |
The present invention provides a benzoheterocycle substituted tetrahydroisoquinoline compound, and in particular, relates to a compound shown in formula (I) and a pharmaceutically acceptable salt thereof, and the compound for the treatme...
|
|
WO/2022/129365A1 |
The present invention relates to novel 1,4-substituted piperidine compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing thes...
|
|
WO/2022/131354A1 |
Provided is a solid formulation that has excellent stability and that is useful for treating or improving (or alleviating) dysuria regardless of the presence/absence or the severity of prostatic hyperplasia. The solid formulation inclu...
|
|
WO/2022/127050A1 |
A compound of formula I or a pharmaceutically acceptable salt, isomer, prodrug, polymorph or solvate thereof, a preparation method therefor, a pharmaceutical use thereof and a pharmaceutical composition comprising same. The compound has ...
|
|
WO/2022/124219A1 |
Provided is a therapeutic agent for diagnosing and preventing IgA nephropathy, the therapeutic agent searching for novel components that contribute to the mechanism of development of the disease. The present invention is a method for m...
|
|
WO/2022/120791A1 |
Disclosed is novel use of selepravastatin, namely an application of selepravastatin in preparation of a medicine for treating nephropathy. The application has the advantages that a novel medicine for treating nephropathy is provided. The...
|
|
WO/2022/122773A1 |
The present invention relates to 4-(2-Fluoro-4-methoxy-5-3-(((l- methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)
carbamoyl)phenoxy)-l-methylcyclohexane-l-carboxylic acid derivatives and similar compounds of formula (I) as R...
|
|
WO/2022/122010A1 |
Provided is an application of a JAK inhibitor in kidney disease. Specifically, provided is a use of a JAK inhibitor in the preparation of a drug for treating or preventing kidney disease.
|
|
WO/2022/121118A1 |
Provided is a humanized anti-IL-4Rα single domain antibody. The antibody has a complementarity determining region and a humanized and modified framework region, the affinity and a tumor cell proliferation blocking effect are maintained,...
|
|
WO/2022/120442A1 |
This invention provides novel codrugs having covalently bound promoieties displaying angiotensin II type 1 receptor (AT1) antagonism and neprilysin (NEP) inhibition and processes of manufacturing thereof. The invention also includes phar...
|
|
WO/2022/125007A1 |
The present invention relates to a prolonged release formulation comprising mirabegron or a pharmaceutically acceptable salt thereof as active ingredient in which release profile of the active ingredient is controlled by using a specific...
|
|
WO/2022/122914A1 |
The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particula...
|
|
WO/2022/122889A1 |
The present invention relates to a method for measuring the activation of mTOR pathway in a subject suffering from a kidney disease associated with a dysregulation of the mTOR pathway comprising the following steps: i) Obtaining urine sa...
|
|
WO/2022/126129A1 |
Provided are methods of administering synthetic tri terpenoids, such as bardoxolone methyl or omaveloxolone, to a patient in need thereof while avoiding adverse drug interactions with cytochrome P450 3A4 (CYP3A4) modulators. Such treatme...
|
|
WO/2022/117060A1 |
Provided is a pharmaceutical composition comprising an anti-connective tissue growth factor antibody. In another aspect, further provided is a use of the pharmaceutical composition comprising an anti-connective tissue growth factor antib...
|
|
WO/2022/117862A1 |
The present invention relates to a pharmaceutical preparation comprising clopidogrel, or a salt or solvate thereof, for use in the treatment of focal segmental glomerulosclerosis (FSGS).
|
|
WO/2022/118966A1 |
A purpose of the present invention is to provide an agent for promoting the uptake of nucleic acid molecules into cells. The present invention relates to, inter alia, an agent for promoting the uptake of nucleic acid molecules into cel...
|
|
WO/2021/089559A9 |
The present disclosure relates to a method of treating kidney injury, by administering an anti-IL- 33 therapeutic agent which inhibits both ST2 signaling and RAGE signaling.
|
|
WO/2022/117062A1 |
The present disclosure relates to fused tricyclic ring-containing compounds and the pharmaceutical use thereof. Such compounds can be used for treating P2X3 activity-related diseases. Exemplary compounds are as represented by formula I, ...
|
|
WO/2022/117864A1 |
The present invention relates to a pharmaceutical preparation comprising genistein, or a salt or solvate thereof, for use in the treatment of focal segmental glomerulosclerosis (FSGS).
|
|
WO/2022/118282A1 |
The present disclosure relates to a composition for use in the treatment or therapy of diseases caused by a peripheral nerve injury, comprising a polymer and a functional group able to bind to an antibody and/or a growth factor, wherein ...
|
